ROCKWELL MEDICAL INC (RMTI)
US7743743004 - Common Stock
Overall RMTI gets a fundamental rating of 2 out of 10. We evaluated RMTI against 195 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of RMTI have multiple concerns. RMTI is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
RMTI had negative earnings in the past year.
RMTI had a negative operating cash flow in the past year.
In the past 5 years RMTI always reported negative net income.
RMTI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
RMTI has a Return On Assets of -17.66%. This is comparable to the rest of the industry: RMTI outperforms 56.92% of its industry peers.
Looking at the Return On Equity, with a value of -43.18%, RMTI is in line with its industry, outperforming 50.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.66% | ||
| ROE | -43.18% | ||
| ROIC | N/A |
ROA(3y)-49.01%
ROA(5y)-57.04%
ROE(3y)-503%
ROE(5y)-358.95%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 10.11%, RMTI is doing worse than 82.56% of the companies in the same industry.
RMTI's Gross Margin has declined in the last couple of years.
RMTI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 10.11% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.55%
GM growth 5Y-2.8%
2. Health
2.1 Basic Checks
RMTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for RMTI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
RMTI has an Altman-Z score of -8.49. This is a bad value and indicates that RMTI is not financially healthy and even has some risk of bankruptcy.
RMTI's Altman-Z score of -8.49 is on the low side compared to the rest of the industry. RMTI is outperformed by 75.38% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that RMTI is not too dependend on debt financing.
RMTI has a Debt to Equity ratio (0.26) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.49 |
ROIC/WACCN/A
WACC10.48%
2.3 Liquidity
A Current Ratio of 1.32 indicates that RMTI should not have too much problems paying its short term obligations.
With a Current ratio value of 1.32, RMTI is not doing good in the industry: 86.15% of the companies in the same industry are doing better.
A Quick Ratio of 1.06 indicates that RMTI should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.06, RMTI is not doing good in the industry: 82.05% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.32 | ||
| Quick Ratio | 1.06 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 70.90% over the past year.
The Revenue has grown by 17.45% in the past year. This is quite good.
The Revenue has been growing slightly by 4.91% on average over the past years.
EPS 1Y (TTM)70.9%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q82.5%
Revenue 1Y (TTM)17.45%
Revenue growth 3Y5.9%
Revenue growth 5Y4.91%
Revenue growth Q2Q27.19%
3.2 Future
RMTI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.63% yearly.
The Revenue is expected to grow by 16.25% on average over the next years. This is quite good.
EPS Next Y79.6%
EPS Next 2Y39.61%
EPS Next 3Y26.63%
EPS Next 5YN/A
Revenue Next Year20.55%
Revenue Next 2Y12.89%
Revenue Next 3Y13.1%
Revenue Next 5Y16.25%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RMTI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RMTI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RMTI's earnings are expected to grow with 26.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.61%
EPS Next 3Y26.63%
5. Dividend
5.1 Amount
No dividends for RMTI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ROCKWELL MEDICAL INC
NASDAQ:RMTI (4/22/2024, 7:25:15 PM)
1.515
+0.06 (+4.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap44.43M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.66% | ||
| ROE | -43.18% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 10.11% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.32 | ||
| Quick Ratio | 1.06 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)70.9%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y79.6%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)17.45%
Revenue growth 3Y5.9%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y